Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose nearly 4% and the generic BCMA CAR-T product CT0596 was clinically approved domestically

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by nearly 4%. As of press release, it had risen 3.9% to HK$14.65, with a turnover of HK$26.376,600.

According to the news, on August 4, Keji Pharmaceutical announced that CT0596, a self-developed BCMA-targeted generic CAR-T cell product, has officially obtained the implied clinical trial license from the State Drug Administration and is intended for use in patients with relapsed/refractory multiple myeloma (R/R MM) who have undergone at least three lines of treatment, marking that the product has officially entered the registered clinical development stage.

According to public information, CT0596 has previously carried out researcher-initiated clinical studies in people with relapsed/refractory multiple myeloma and plasma cell leukemia, and relevant positive data was published in the form of a poster at the 2026 European Hematology Association (EHA) annual meeting. The approval of the IND is a key milestone in the transition from early clinical exploration to standardized registration and development of the product.